Which COVID-19 vaccines are covered?

A new report from The New York Times paints a grim picture of the prospects for many COVID vaccines, with only 12 percent of them covered by the government.

While the authors argue that more than half of the vaccine makers have committed to the program, they also note that many of them aren’t making any money from it.

The report, co-authored by reporter John Bresnahan, found that while some vaccines have been approved for sale in the U.S., the majority of them are only covered by a small pool of state and local health authorities.

The report notes that in many cases, those vaccine makers were simply required to comply with federal requirements in order to sell vaccines to the public.

The Times also found that about 80 percent of the vaccines that have been made available in the United States have not been covered by any insurance coverage at all.

Only one vaccine, GlaxoSmithKline’s (GSK) COVID2 vaccine, is covered by insurance.

The paper also notes that about 90 percent of vaccines sold in the country are not covered by Medicare.

In addition to the Times article, a new report by The Associated Press found that nearly half of all vaccines available in America have no insurance coverage.

The researchers said that more Americans are buying COVID vaccine for the first time in decades than ever before.

A new report out today by the Associated Press shows that nearly a quarter of the U,S.

vaccines available to consumers have no coverage, and many of the largest vaccine makers are either not making money from the program or are not paying for insurance.

The Associated Press, citing figures from the Centers for Disease Control and Prevention (CDC), found that more people have been buying the vaccine than any other drug, a result of the government’s decision to phase out some of its stockpile.

But while the vaccine is being phased out, it has been getting a little better coverage, thanks to a handful of vaccine makers, including Glaxos and Cervarix.

“It’s a big problem,” said David Katz, the chief executive officer of Glaxocare, the largest provider of COVID vaccination.

“They can’t be selling it on the street because there is no insurance.

But they have to sell it to insurers, because insurance doesn’t cover them.””

When the government started shutting down the vaccine, they started selling it in small batches.

Now it’s a $10 million per year program,” Katz said.

“But they have not taken a penny out of it.

They are just going to keep it out there.”

The New York study also found more than one-third of vaccines were not covered under Medicare, with one vaccine maker, Merck, getting about a quarter coverage, while one vaccine manufacturer, Pfizer, received just over half coverage.

The New Yorker reports that about 50 percent of those who bought vaccines in the last few months of the year reported receiving a refund.

The Times article also found the federal government has spent more than $400 million to cover COVID outbreaks.

The National Vaccine Information Center, a nonprofit group that tracks vaccine manufacturers, said that the CDC is providing an estimated $8.4 billion in vaccine reimbursements to the vaccine companies, including $3.5 billion for vaccine manufacturers.

However, many vaccine makers say they are losing money because the government has not been paying for their COVID investments.

In fact, the vaccine industry is spending more than it has ever in a single year.

The group estimates that about $7.5 million in vaccine sales have been taken out of the program.

The government is spending $1.5 to $3 billion per vaccine, depending on how the vaccines are distributed.

In some states, some vaccine manufacturers have been allowed to charge a premium for vaccines sold to the general public, according to the AP.

In Texas, for example, Mercy Medical Group (MGM) is the only vaccine maker that charges a surcharge for any COVID product sold to anyone who is at least 18 years old, according the report.

The surcharge, which is only available to people who are residents of the state, is a one-time payment of $25 to $150 per dose.

According to the report, Merciys price is based on a standard of care of about $6,000 per person per year, which means it is possible for a patient who is eligible for Medicaid to pay $12,000 for the vaccine.

The AP report notes the surcharge is being paid by Merciies parent company, Glargys Pharmaceuticals.

In the United Kingdom, a government initiative to cover all COVID deaths has been rolled out for three years, but the government still has not covered the costs of vaccine distribution and testing.

The Department for International Development (DFID) announced last month that the government will cover 90 percent, with a few other countries still not getting their vaccines distributed.

The government has been running its CO